Thank you for the submission of your manuscript to EMBO reports. We have just now received the full set of reports from the referees, which I copy below. As all three referees think that your manuscript is interesting and their comments are quite positive, I would like to ask you to revise it according to the referees' comments.
Thank you for the submission of your manuscript to EMBO reports. We have just now received the full set of reports from the referees, which I copy below. As all three referees think that your manuscript is interesting and their comments are quite positive, I would like to ask you to revise it according to the referees' comments.
In his/her report, Referee #1 expresses three major concerns that need to be addressed. First, s/he considers that it is important to show that full-length PAPC shows effects similar to its cytoplasmic domain alone. S/he is also concerned with a potential non-autonomy of PAPC effects that need explanation. Third and last, s/he is concerned with the possibility of PAPC and CK2-beta acting independently of each other. Referees #2 and #3 agree with referee #1 in this point and suggest several experiments to further strengthen the hypothesis that PAPC inhibits Wnt signaling through CK2-beta. Referee #2 also remarks that given that distinction between canonical and non-canonical Wnt signaling is a major issue in the field, it should be more thoroughly discussed.
Given these evaluations and the potential interest of your study, I would like to give you the opportunity to revise your manuscript, with the understanding that the referee concerns must be fully addressed and their suggestions (as detailed above and in their reports) taken on board. Acceptance of the manuscript will depend on a positive outcome of a second round of review and I should also remind you that it is EMBO reports policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
I look forward to seeing a revised version of your manuscript when it is ready.
Yours sincerely, Editor EMBO reports REFEREE REPORTS:
The manuscript describes a novel function of a protocadherin, Xenopus PAPC, claiming that it inhibits canonical Wnt/β-catenin signaling by sequestering Casein Kinase 2β. This observation should be of interest in the wider field of cell signaling/signaling pathways, and in particular to researchers studying Wnt signaling in a developmental context. The manuscript is of appropriate length, and clearly written. However, there are three main concerns which should be addressed:
1) In the model of Fig.3B , PAPC is depicted as sequestering CK2β, thus removing it from the canonical pathway. However, in the experiments described, the cytoplasmic domain of PAPC was used throughout to interfere with canonical signaling. It would be important to show that the fulllength PAPC can also diminish canonical signaling, and desirable to demonstrate its binding of CK2β (membrane recruitment of tagged CK2β?).
2) From Fig.2C , it appears as if in PAPC-MO embryos, Xnr3 expression is expanded far beyond the PAPC expression domain. In particular, expression in the ectoderm seems to be upregulated. Is that so? Perhaps better images, with higher resolution, could be provided. If true, this would suggest that the effect is not cell-autonomous, which would pose a problem for the model that is suggested. An alternative model would then be required.
3) Fig.2B : the fact that an inhibitory CK2β construct reduces PAPC-MO induced Xnr3 expression to wildtype levels does not necessarily demonstrate that PAPC suppresses Wnt signaling through its interaction with CK2β. It could be the endogenous component of the Xnr3 expression which is reduced by CK2βKI, with the induced component being unaffected. Would it be possible to provide additional evidence for PAPC functioning through CK2β binding in this type of assay? A synergy of sub-threshold PAPC-MO and CK2β in the induction of Xnr3?
Referee #2:
In the present manuscript "Xenopus Paraxial Protocadherin inhibits Wnt/β-catenin signaling via Casein Kinase 2β" Kietzmann et al. demonstrate that Xenopus PAPC interferes with the canonical Wnt pathway by inhibiting Casein Kinase 2β. They show that both proteins directly bind to each other and that amino acids 900-920 of PAPC are required for this interaction. Moreover, their experiments reveal that the c-terminal part of PAPC is sufficient to suppress CK2β-mediated induction of the Xenopus canonical Wnt target xnr3 in animal caps and that knockdown of PAPC is sufficient to increase endogenous canonical Wnt signaling in vivo on the dorsal side of the early Xenopus embryo. These results reveal a very interesting new role for PAPC during early axis formation and for canonical Wnt signaling and is therefore well suited for publication in EMBO reports. The inhibitory and restrictive influence of PAPC on the canonical Wnt pathway is very convincing. In addition, the interaction of PAPC and CK2β are nicely shown and need no further proof.
Mayor point:
To further emphasize that the mechanism of negative PAPC influence on canonical Wnt signaling is mediated by inhibition of CK2, it would be good to test whether ventrally overexpressed PAPCc is able to prevent CK2α/β-mediated induction of double axes (Dominguez et al). Did the authors test this? If this is not possible, then the authors could further strengthen the inhibitory effect of PAPCc on Xnr3 shown by real time PCR in Fig. 2B . For example, does CK2α/β overexpression on the dorsal also increase endogenously Xnr3 expression (as PAPC-MO does) and can this be inhibited by PAPCc co-injection?
Minor points: 1. In Fig. 2A , indicate in the ordinate that Xnr3 is being measured 2. In Fig. 3A , indicate in the ordinate that what is being measured (i.a. a Siamois-Luc reporter) 3. The very interesting outcome of this study is that PAPC not only has a positive role in noncanonical Wnt signaling but also a negative one in the canonical pathway via CK2 inhibition places it in a central position where those pathways interact. The opposition between non-canonical and canonical Wnt signaling is a mayor biological issue. I am aware that there is limited space for discussion but yet I like to suggest putting emphasis on the fact that PAPC might be a key regulator for the choice between canonical and non-canonical Wnt activation.
The manuscript's data are of quality and the findings novel and intriguing. The conclusions on the role of PAPC in Wnt/β-catenin signaling will be stronger if more than one Wnt/β-catenin target gene is analyzed. Even though figure 1 suggests an interaction between CK2β and PAPC, there is not link between CK2β and PAPC effects on Wnt/β-catenin signaling in the manuscript. This should be shown (see below).
Comments: 1. The authors should revise the conclusion from Figure 1C : "...show that amino acids 900-920 of the xPAPC protein are required for the interaction with CK2β ( Figure 1C )." as it does not completely describe the results shown. Amino acids 900-920 were not sufficient to bind CK2β and the addition of amino acids 837-899 resulted in binding that was enhanced by addition of amino acids 715-836. The authors should also revise the + sings in the figure to match the results (e.g. the 715-899 fragment should have a + sign).
2. In figure 1B the western blot for α-flag in the input should also be shown.
3. The mutant used in figure 2 (papccflag aa715-899) still retains some ability to bind CK2β. Is this the reason why the effect in animal caps and whole embryos was modest? Or is this due to low levels of expression of the mutant protein? Have the authors tried different doses of the mutant mRNA resulting in better inhibition? According to the author's hypothesis, CK2β mediates PAPC effects but this is not shown: Does CK2β rescue the effect of PAPCc on Xnr3 expression? Conversely, the mutant papccflag aa715-899 should not decrease Xnr3 expression in any one of these assays.
4. The conclusions from figure 2A will be strengthen by analysis of other Wnt/β-catenin target genes such as siamois, and showing comparable levels of exogenous protein expression in the experiment.
5. Authors should add whether the data obtained in Figure 2B was statistically significant.
6. In the histogram in figure 2C , what does expanded, unchanged and reduced mean for the wt embryos (= endogenous expression of Xnr3)? 7. What is the resulting phenotypic effect of PAPC-MO in whole embryos? How does it relate to other phenotypes with increased Wnt/β-catenin signaling (e.g. the Wnt8 injection?) 8. What are the effects of PAPCc on the siamois reporter? Can this effect, if any, be rescued by CK2β? Conversely, does mutant papccflag aa715-899 have any effect in reporter activation?
9. Does dorsal expression of CK2β expand the Xnr3 expression domain?
Overselling claims: 1. The experiment to reach the conclusion found in page 7 ("This inhibitory effect of PAPC is dependent on the binding of the regulatory subunit CK2β to the cytoplasmic domain of PAPC"), was not performed. See comments 3, 8 and 9.
2. The experiment to reach the conclusion found in page 7 ("..... In the case of Xenopus PAPC this inhibition is achieved by modulation of CK2 activity.) was not performed. There is no analysis of CK2 activity in the manuscript. In addition, removal of CK2β may not change the activity of CK2 but may change the substrate specificity of the enzyme.
Notes to the discussion and introduction: 1. Since PAPC has signaling functions and CK2β can bind several proteins in a CK2α dependent or independent manner, is it possible that CK2β plays a role in PAPC signaling role?
2. Correction and references missing: Essential components of the Wnt/β-catenin pathway such as Dishevelled (Dsh) and β-catenin are substrates for the CK2 complex (Song et al., 2003; Willert et al., 1997) . Phosphorylation by CK2 precedes that of CK1ε in Dsh, and stabilizes β-catenin in the cytoplasm, which is essential for nuclear entry and In this manuscript we show that the intracellular domain of the Xenopus Paraxial Protocadherin (PAPC) interacts with CK2β, a positive regulator of the Wnt/β-catenin pathway. Binding of CK2β to PAPC inhibits CK2-mediated activation of the Wnt pathway and knock-down of PAPC function in Xenopus embryos results in elevated levels of Wnt/β-catenin signal. This indicates that PAPC acts in vivo as an inhibitor of Wnt signaling which restricts the expression of Wnt target genes during gastrulation. Our experiments demonstrate for the first time that a protocadherin can act as an inhibitor of the Wnt/β-catenin pathway and reveal a novel mechanism of intracellular regulation of Wnt signaling.
In your decision letter you listed 4 points of concern that were raised by the referees.
1.)…..to show that full-length PAPC shows effects similar to the cytoplasmic domain alone.
By conventional RT-PCR and qRT-PCR we could show that Fl-PAPC inhibits CK2α/β induced transcription of Wnt target genes ( Fig. 2; S1 ).
2.)…concerned with the potential non-autonomy of the PAPC effects.
The induction of nr-3 expression in the ectoderm found in embryos in which PAPC was knocked down can be explained by the ability of the nr-3 proform to inhibit BMP-4 protein (Haramoto et al., 2006, BBRC) . BMP signaling inhibts the Wnt/β-catenin pathway, ventralizes the embryo and prevents the formation of neural tissue. In the Xenopus gastrula only the dorsal blastopore lip (Spemann-Mangold organizer) is not expressing BMP-4 and the inhibition of BMP causes hyperdorsalization. In PAPC Morpholino injected embryos Wnt signaling is elevated and more nr-3 protein is produced. Since nr-3 is a secreted factor it could inhibit BMP signaling in the dorsal ectoderm which would result in the induction of nr-3 expression in this tissue. We have included this line of argument in the "results and discussion" section (p. 6).
3.)……concerned with the possibility that PAPC and CK2β acting independently of each other.
In order to strengthen our argument that PAPC inhibits Wnt/β-catenin through CK2β we have included 3 new sets of experiments: a. In membrane recruitment assays we show that in the presence of PAPC CK2β-GFP is redistributed to the membrane (Fig.1D) . b. We show that that PAPC antagonizes the expression of the Wnt targets nr-3 and sia which was induced in ventral mesoderm by ectopic expression of CK2α/β (Fig.2B) . c. We demonstrate that knock-down of PAPC synergizes with overexpression of CK2α/β in the activation of Wnt targets (Fig.4A ). 4.)…….distinction between canonical and non-canonical Wnt-siganling and the role of PAPC. In the "conclusion" section we discuss the possibility that PAPC could mediate the inhibition of the canonical Wnt pathway by non-canonical Wnt signaling. PAPC can interact with ANR-5 and Sprouty 1 and thereby promotes PCP signaling. The binding of CK2β on the other hand inhibits canonical Wnt signaling. In the presence of PAPC the PCP pathway is augmented and simultaneously the Wnt/β-catenin pathway is inhibited (p. 8).
Referee1
1.) The referee found it important to show that the FL-PAPC is able to bind CK2β and can diminish Wnt/β-catenin signaling. We have included PCR data showing that FL-PAPC can inhibit CK2 induced Wnt target gene expression ( Fig.2A, S2) . In order to show the interaction of FL-PAPC and CK2β we included membrane recruitment assays showing that PAPC bring GFP-tagged CK2β to the membrane (Fig.1D) .
2.) The referee pointed out that the expression domain of nr-3 in PAPC Morpholino injected
embryos expanded into the ectoderm, where no endogenous PAPC is expressed. The induction of nr-3 expression in the ectoderm found in embryos in which PAPC was knocked down can be explained by the ability of the nr-3 proform to inhibit BMP-4 protein (Haramoto et al., 2006, BBRC) . BMP signaling inhibts the Wnt/β-catenin pathway, ventralizes the embryo and prevents the formation of neural tissue. In the Xenopus gastrula only the dorsal blastopore lip (Spemann-Mangold organizer) is not expressing BMP-4 and the inhibition of BMP causes hyperdorsalization. In PAPC Morpholino injected embryos Wnt signaling is elevated and more nr-3 protein is produced. Since nr-3 is a secreted factor it could inhibit BMP signaling in the dorsal ectoderm which would result in the induction of nr-3 expression in this tissue. We have included this line of argument in the "results and discussion" section (p. 6).
3. In order to provide additional evidence that PAPC functions through CK2β the referee suggested a synergy experiment of sub-threshold concentrations of PAPC-Mp and CK2α/β. We performed this experiment and demonstrate that knock-down of PAPC synergizes with over expression of CK2α/β in the activation of Wnt targets. This finding was incorporated into the results as Fig.4 A.
Referee 2
Major point To further emphasize the mechanism of negative influence of PAPC on canonical Wnt signaling the referee suggested to express CK2α/β on the ventral side of Xenopus embryos and analyze the inhibitory effect of PAPC. We have performed this experiment and show that that PAPC antagonizes the expression of the Wnt targets nr-3 and sia which was induced in ventral mesoderm by ectopic expression of CK2α/β (Fig.2B) .
Minor points 1, 2.) correct labeling of sub-figures (Indicate what was measured).
We have improved labeling of the indicated figures 3.) The referee pointed out that our data put PAPC at the intersection between canonical and non-canonical Wnt signaling and encouraged discusseing PAPC as a regulator for the choice between the two branches of the Wnt pathway. We have addressed this point now in the "conclusion" section where we discuss the possibility that PAPC could mediate the inhibition of the canonical Wnt pathway by non-canonical Wnt signaling. PAPC can interact with ANR-5 and Sprouty 1 and thereby promote PCP signaling. The binding of CK2β on the other hand inhibits canonical Wnt signaling. In the presence of PAPC the PCP pathway is augmented and simultaneously the Wnt/β-catenin pathway is inhibited. (p. 8).
Referee 3 1.) The referee pointed out that that the PAPC deletion 715-899 interacted weakly with CK2β in the Y2H system. We revised our conclusion and state now that this mutant interacts weakly with CK2β (Fig.1B) . In addition we included the 715-899 deletion into the co-IP experiments. The weak interaction was confirmed in this assay (Fig.2C) .
2.)
The referee requested to show the input control for the western blot (Fig.1B) . We have included a new co-IP experiment including the input control (Fig.2C) .
3.) The referee was concerned about the protein levels of the different PAPC constructs
We have included western blot data indicating that all construct used are expressed and stable (Fig.S2) . qRT-PCR analysis confirmed that the PAPC 715-899 deletion was not able to inhibit nr-3 expression (S1)
4.) The referee suggested to analyze the additional Wnt target sia.
We have included the sia marker and present the data in Fig. 2B and Fig.4A .
5.) Statistical relevance of data from Fig.2B
Statistical relevance is presented for this figure (now Fig.3C ).
6.) Definition of the terms: "expanded, unchanged reduced" used in Fig.2C . We made clear in the figure, the legend and the text that we compare the expression domain of nr-3 in manipulated embryos to the wt pattern.
7.) Do PAPC-MO and gain of Wnt-8 have similar phenotypic effects?
The phenotypic effects of PAPC-Mo were described in Medina et al., 2004 , EMBOJ. The authors did not observe dorsalized phenotype as seen after Wnt-8 overexpression. The moderate elevation of Wnt signaling on the dorsal side by PAPC knock down can be counteracted by autoregulatory mechanism that are active in the Spemann-Mangold organizer. It was reported that moderate modulation of nodal signaling on the dorsal side of Xenopus embryos affects expression of marker genes during gastrulation but no phenotypic effects can be detected at tailbud stages ( Martello et al., 2007, Nature, 449, 183-186) .
8.) What are the effects of PAPCc on the sia reporter?
We have not tested the effect of PAPC on the sia reporter but we include a PCR experiment showing that PAPCc can reduce nr3 expression by about 60%. In contrast a PAPC deletion lacking the amino acids 900-920 failed to down-regulate nr-3 expression (S3). Interestingly this deletion construct strongly up-regulates nr-3 expression.
9.) Does dorsal expression of CK2α/β expand the nr-3 domain. We have not performed this experiment and since the dorsalizing activity of CK2α/β is well described an enhancement of dorsal marker gene expression is expected.
Overselling claims
1.) Since we included new data strengthening the connection between CK2β and PAPC we find the statement that the inhibitory effect of PAPC is mediated through binding of CK2β justified. 2.) We agree with the referee that no CK2 activity was measured and revised the mentioned statement on page 6.
Notes to the discussion and the introduction 1.) The role of CK2 in PAPC signaling function. This is a very interesting aspect the referee raised. Since we have no data on this subject in the manuscript and due to space limitations we were unable to discuss this issue.
2.) Correction and references missing
We have incorporated the references as the referee requested.
